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Human immunodeficiency virus type 1 (HIV-1) protease activity is targeted at nine cleavage sites comprising different
amino acid sequences in the viral Gag-Pol polyprotein. Amino acid polymorphisms in protease and in regions of Gag,
particularly p7NC and the C-cleavage site between p2 and p7NC, occur in natural variants of HIV-1 within infected patients.
Studies were designed to examine the role of natural polymorphisms in protease and to identify determinants in Gag that
modulate protease processing activity. Closely related Gag-Pol regions from an HIV-1-infected mother and two children were
evaluated for processing in an inducible expression system, for protease activity on cleavage-site analogues, and for impact
on replication by recombinant viruses. Gag-Pol regions displayed one of three processing phenotypes based on the
appearance of Gag intermediates and accumulation of mature p24CA. Gag-Pol regions that were processed rapidly to produce
p24CA resulted in high-level replication by recombinant viruses, while slow-processing Gag-Pol variants resulted in recom-
binant viruses that replicated with reduced kinetics in both T cell lines and peripheral blood mononuclear cells. Direct impact
by Gag sequences on processing by protease was assessed by construction of chimeric Gag-Pol regions and by site-directed
mutagenesis. Optimal protease activity occurred when Gag and Pol regions were derived from the same gag-pol allele.
Heterologous Gag regions generally diminished rates and extent of protease processing. Natural polymorphisms in novel
positions in p7NC and the C-cleavage site have a dominant effect on protease processing activity. Accumulation of Gag
CAproducts after processing at the C site appears to delay subsequent cleavage and production of mature p24 . © 2002 Elsevier
ScienceINTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) protease
(PR) is encoded in the pol region of the viral genome and is
essential for virus infectivity (Kaplan et al., 1994, 1996; Kohl
et al., 1988; Peng et al., 1989). PR is an aspartic protease
that cleaves HIV-1 Gag and Gag-Pol polyproteins to pro-
duce PR, reverse transcriptase, and integrase, as well as
matrix (p17MA), capsid (p24CA), and nucleocapsid (p7NC)
(Oroszlan and Luftig, 1990; Skalka, 1989). PR recognizes
and cleaves eight or nine target sites that differ in amino
acid sequence in the Gag-Pol polyprotein (Griffiths et al.,
1992; Pearl and Taylor, 1987). PR processing is an ordered
process that leads to virion maturation (Tritel and Resh,
2000). Sequential cleavage at target sites has been defined
in virions and in bacterial or mammalian cells in the ab-
sence (Bloom et al., 1998; Erickson-Viitanen et al., 1989;
Krausslich et al., 1989; Pettit et al., 1994; Wiegers et al., 1998)
or presence of protease inhibitors (PI) (Melnick et al., 1998;
Speck et al., 2000).
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137PR processing activity depends on the primary amino
acid sequence of PR, the composition of the cleavage
sites, and determinants in Gag. PR is a dimeric enzyme
comprising identical 99-amino-acid subunits, while tar-
get cleavage sites in Gag or Pol comprise approximately
10 amino acids (Dunn et al., 1994; Jupp et al., 1991; Partin
et al., 1990). Determinants within PR, namely the oxida-
tion state of the conserved cysteine residues, protein
folding near the N-terminus, or mutations in the flap
region of the enzyme, regulate polyprotein processing
(Davis et al., 1999; Louis et al., 1999a; Shao et al., 1997).
In addition, exogenous factors such as the levels of
ubiquitination and proteasome inhibition can interfere
with Gag polyprotein processing (Schubert et al., 2000).
Although sequences that impact PR activity are distrib-
uted throughout the Gag polyprotein, several studies
implicate p7NC as a critical domain (Barrie et al., 1996;
Kawamura et al., 1997). For the most part, mutagenesis of
laboratory strains, such as HIVLAI or closely related
HIVHXB2, has provided insights into mechanisms of PR
activity in Gag-Pol processing (Pettit et al., 1994; Tritch et
al., 1991). Genetic variability of HIV-1 results in Gag-Pol
alleles in viruses from infected individuals that differ from
laboratory strains and display natural amino acid poly-
morphisms at multiple positions in PR, in the C-cleavage
0042-6822/02 $35.00
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138 GOODENOW ET AL.site at the amino end of p7NC, and within p7NC (Barrie et
al., 1996). Impact of genetic variability in Gag-Pol on PR
activity from patient variants of HIV-1 could contribute to
differences in virus replication and response to antiret-
roviral drugs, such as PI (Croteau et al., 1997; Doyon et
al., 1996; Erickson and Eissenstat, 1999; Goodenow et al.,
2000; Mammano et al., 1998; Zennou et al., 1998; Zhang
et al., 1997).
PR alleles from individuals infected by unrelated
strains of HIV-1 display multiple differences in nucleotide
and amino acid sequence (Barrie et al., 1996; Lech et al.,
1996; Perez et al., 2001; Servais et al., 2001). In contrast,
viruses from individuals infected by a similar source
display closely related sequences with only a small num-
ber of amino acid differences in PR and in p7NC (Barrie et
al., 1996). In previous studies, we found that amino acids
in PR and in the C-cleavage site between p2 and p7NC
segregated by epidemiology, implying that a critical as-
sociation may exist between a particular PR allele and its
cognate C-site peptide (Barrie et al., 1996). To evaluate
directly PR processing activity and associations between
PR and Gag, gag-pol alleles from three individuals,
namely a mother and her two children, who were in-
fected by related viruses were assayed in an inducible
expression system and by virus replication. A functional
linkage between PR and sequences in Gag that map to
the C-cleavage site and to novel determinants in p7NC
was identified. Accumulation of Gag products after pro-
cessing at the C site can impact subsequent cleavage
and production of p25 and mature p24CA. Results suggest
that amino acid sequences in p7NC can delay dissocia-
tion between PR and Gag.
RESULTS
Different processing phenotypes by genetically
related gag-pol alleles
PR processing of Gag-Pol was evaluated in an IPTG-
inducible expression and processing assay. Unpro-
cessed Gag-Pol polyprotein expressed from the HIVHXB2
gag-pol region included in the expression vector would
migrate at about 110 kDa, which reflects truncation of
eight amino acids from the amino terminus of p17MA,
deletion from Pol of most of the reverse transcriptase
(RT) and integrase, and a frameshift that was introduced
between the D9 and the D cleavage sites (Fig. 1A). A
monoclonal anti-p24 antibody was used to detect un-
processed p110Gag-Pol and four smaller proteins that in-
clude p24CA and would be produced by sequential pro-
cessing at cleavage sites E, C, A, and B (Bloom et al.,
1998; Erickson-Viitanen et al., 1989; Krausslich et al.,
1989; Pettit et al., 1994; Wiegers et al., 1998) (Fig. 1A). PR
processing at the E site produces p54, while cleavage at
the C site, which is located between p2 and p7, produces
MAp40. Subsequent processing at the A site between p17
and p24CA produces a 25-kDa protein, followed by cleav-age at the B site leading to p24CA (Fig. 1A). The strategy
to evaluate gag-pol regions of HIV-1 from patients re-
sulted in maintenance of the A-cleavage site from the
HIVHXB2 backbone, while other cleavage sites were de-
rived from patient viruses (Fig. 1A, gray region).
Three gag-pol alleles, which represented the major
sequence from three HIV-infected patients (siblings D1
and D2 and their mother MD) displayed different pro-
cessing phenotypes (Fig. 1B). D1.10 Gag-Pol was pro-
cessed rapidly to produce p25 as early as 5 min follow-
ing induction with IPTG (Fig. 1B, blot 1). Subsequent
processing of p25 to produce p24 was evident by 15 min
postinduction. Appearance of p25 and p24 was consis-
tent with sequential processing first at the C and A sites,
followed by processing at the B site. Rapid, complete
processing with virtually no accumulation of Gag p54 or
p40 intermediates was termed a Type I processing phe-
notype. Detectable processing was dependent on intro-
duction of the ribosomal frameshift. For example, a gag-
pol construct without a frameshift produced a precursor
protein of about 54 kDa, which corresponded to unpro-
cessed Pr54Gag that terminated in p6 (Fig. 1B, lane A).
Processing was also dependent on induction of expres-
sion. In the absence of IPTG treatment, no products were
detected (Fig. 1B, lane C).
Type II processing (intermediate/complete) phenotype
was displayed by D2.21 and was characterized by tran-
sient accumulation of p54 during the first 15 min follow-
ing induction (Fig. 1B, blot 2). Gag p40 was produced as
early as 5 min, although subsequent appearance of p25
was delayed for 20 min. Appearance of p25 occurred
concomitantly with a reduction in p40 and production of
p24. HIVLAI processing of Gag-Pol polyprotein displayed
a Type II processing phenotype (data not shown).
Type III processing was exhibited by MD.03 and was
characterized as incomplete based on a failure to pro-
duce detectable p24 (Fig. 1B, blot 3). Pr54Gag and p40
appeared within 5 min following induction, while p40
continued to accumulate during the assay. Even though
processing produced low levels of p25 as early as 5 min
postinduction, accumulation of p25 occurred slowly and
failed to diminish levels of p40. No detectable process-
ing to produce p24 occurred even after 60 min.
Different processing phenotypes were reproducible in
independent assays (data not shown). Results from this
series of experiments suggested that processing at the
C-cleavage site and accumulation of p40 had an impact
on subsequent PR cleavage at A or B sites. Differences
in processing phenotypes might be expected to impact
viral replication.
Processing phenotype is reflected by virus replication
To assess a functional relationship between Gag-Pol
processing and viral replication, recombinant viruses
were constructed by inserting gag-pol fragments, which
omplete
ch was
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clone of HIVLAI. Three recombinant viruses were con-
structed and evaluated for initial replication in compari-
son to wild-type HIVLAI in Jurkat T cells and in peripheral
blood mononuclear cells (PBMC) (Fig. 2). Recombinant
viruses expressing a Type I processing Gag-Pol region
from D1.10 produced 3-fold greater levels of p24 antigen
than HIVLAI, a Type II processing phenotype, at 4 days of
culture (Fig. 2A). Recombinant viruses with D2.21 gag-pol
region, which had a Type II processing phenotype, rep-
licated over the course of 5 days to levels that were
FIG. 1. Processing phenotype of Gag-Pol polyprotein. (A) Schemat
induction with IPTG. Arrows and letters designate cleavage sites. Pro
antibody (a p24) (dotted line). The gag-pol regions derived from patien
sites into a backbone derived from HIV-1HXB2. A 11 frameshift was intr
pGAG-POL expresses a truncated Gag polyprotein of approximately
polyprotein of about 110 kDa, which initiates in matrix (DMA) and termin
of matrix are included under Materials and Methods. Cleavage at the E
site to produce p40, at the A site to produce p25, and at the B site to
produce the protein. (B) Immunoblot analysis of polyprotein processin
indicated on the left and cleavage sites are indicated on the right of the
Lane B, purified p24 protein standard. Lane C, no IPTG induction of e
minutes following IPTG induction. Roman numbers above the blots des
to p24CA displayed by D1.10 Gag-Pol; Type II, intermediate kinetics and c
but incomplete processing with no detectable p24CA after 60 min, whisimilar to those of HIVLAI (Fig. 2B). Viruses with the
gag-pol region from patient MD.03, which displayedslow, incomplete processing (Type III phenotype), were
replication competent, but produced supernatant levels
of p24 antigen that were 2- to 2.5-fold reduced from the
other viruses (Fig. 2B). Replication by recombinant vi-
ruses in PBMC produced levels of p24 antigen that were
about 10-fold greater than in Jurkat cells (Fig. 2C). Yet, the
relationship among the viruses with variant gag-pol re-
gions for replication levels in PBMC were similar to
results from Jurkat cells. By 4 to 6 days of infection in
PBMC, D1.10 recombinant virus produced levels of p24
antigen that were 2- to 3-fold higher than levels produced
sentation of the Gag-Pol polyprotein expressed by pGAG-POL after
g at sites A, B, C, and E was detected by a monoclonal anti-p24 CA
alleles (gray shading) were introduced at SpeI and EcoRV restriction
at the BglII restriction site located between D9 and D cleavage sites.
the absence of a frameshift. Frameshifted pGAG-POL expresses a
reverse transcriptase (DRT). Details of the frameshift and the initiation
roduces p54, while subsequent cleavage occurs sequentially at the C
p24 MA. Each product is designated by the site that was cleaved to
r IPTG induction of pGAG-POL expression. Gag-specific proteins are
ne A, 54-kDa Gag polyprotein expressed by an unframeshifted variant.
on. In blots 1, 2, and 3, numbers directly above lanes indicate time in
processing phenotype: Type I, rapid kinetics and complete processing
processing displayed by D2.21 Gag-Pol; Type III, intermediate kinetics
displayed by MD.03 Gag-Pol.ic repre
cessin
t HIV-1
oduced
p54 in
ates in
site p
produce
g afte
blot. La
xpressi
ignateby HIVLAI or D2.21, and 5- to 6-fold greater than levels
produced by MD.03 (Fig. 2C).
bols: (
140 GOODENOW ET AL.Gag processing in Jurkat cells by recombinant viruses
with protease variants was evaluated over time. Initial PR
processing in Jurkat cells was undetectable during the
first 24 h with the p24 monoclonal antibody (data not
shown). The Gag products detected by 48 h included
Pr55, p41, and p24CA (Fig. 2D). Each virus produced sim-
ilar steady-state levels of the three Gag proteins for as
long as 4 days (Fig. 2D).
Cleavage of synthetic substrates by PR variants
Processing phenotypes could reflect differences in PR
activity and/or polymorphisms in Gag among the patient
variants. Initial focus was directed to determination of
differences in PR activity. PR alleles from each patient
comprised similar, although not identical, amino acid
sequences that reflected transmission of virus from the
mother (MD) to her children (D1 and D2) (Fig. 3). Pro-
cessing phenotype was unrelated to the number of
amino acid differences between PR alleles from the
FIG. 2. Replication kinetics and Gag-Pol processing by recombina
indicated for days postinfection (abscissa). (A and B) Replication in Jurk
are representative of experiments that were repeated three times. Sym
Gag-Pol processing by recombinant viruses in Jurkat cells.
FIG. 3. Amino acid sequence of PR alleles from patients. PR allele
extensions designate specific PR alleles from patients (Barrie et al., 199
indicated by the single-letter code. Dots above the sequence designate ever
the amino and carboxy ends of PR that are included in the E- or F-cleavagepatients and HIVLAI. For example, PR from D2.21 differed
from HIVLAI PR by seven amino acids, although Gag-Pol
alleles from each displayed Type II (intermediate/com-
plete) processing phenotypes and similar replication by
recombinant viruses. Only two amino acids (G22E and
I62V) differed between Type I-processing D1.10 PR and
Type III-processing MD.03 PR. Amino acids comprising
the E- or F-cleavage sites that flank PR were invariant
among the different patient variants (Fig. 3 and data not
shown).
To evaluate biochemical characteristics of the PR vari-
ants, the 99-residue PR regions from D1.10, D2.21, MD.03,
and HXB2 were expressed, purified, quantified, and as-
sayed for cleavage of three synthetic peptide substrates
that were based on the amino acid sequence of the
B-cleavage site (Table 1). K m values varied approximately
threefold, while k cat values varied only about twofold, for
the four enzymes with each substrate. The specificity
constant, k cat/K m, is the best measure of catalytic effi-
es. Accumulation of p24 antigen levels in supernatants (ordinate) is
lls. (C) Replication in primary peripheral blood mononuclear cells. Data
n ) D1.10, (F) D2.21, () MD.03, (3) HIVLAI. (D) Immunoblot analysis of
patients D1, D2, and MD were aligned relative to HIVLAI. Numerical
h indicates amino acid identity with HIVLAI. Amino acid differences arent virus
at T ces from
6). Dasy 20 amino acid residues in PR. Bars indicate amino acid residues at
sites, respectively.
risk de
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greater than threefold in catalytic efficiency was de-
tected among the four enzymes on any one substrate,
indicating that PR variants had similar, although not iden-
tical, activities (Table 1). Differences were considered
insufficient to account for the variation in efficiency and
completeness of processing at the B-cleavage site in the
bacterial processing assays.
Processing activity by PR using chimeric Gag-Pol
To identify if Gag determinants could contribute to the
processing phenotypes, gag regions between SpeI and
BglII from different alleles were exchanged in nonframe-
shifted Gag-Pol expression vectors, followed by introduc-
tion of a frameshift at the BglII site. Processing of the
chimeric Gag-Pol was evaluated relative to processing of
the parental Gag-Pol polyprotein variants.
When the Gag region from D2.21 was combined with
D1.10 PR, processing by D1.10 PR was diminished (Fig.
4A, blot 2). The Gag p40 intermediate persisted for 20
min, while processing to yield p25 was delayed and
appreciable levels of p24 were evident only after 60 min.
Processing of D2.21 Gag region by PR D1.10 displayed a
Type II processing phenotype.
PR D1.10 processing was significantly impaired when
combined with MD.03 Gag region (Fig. 4A, blot 3). Even
though some processing to produce p54 and p40 inter-
mediates occurred over 60 min, appearance of p25 was
delayed for almost 30 min. Processing of p25 at the B site
to produce p24 failed to occur even after 60 min. Pro-
cessing by the MD.03/D1.10 Gag-Pol chimeric polyprotein
was essentially identical to the Type III phenotype dis-
played when both Gag and Pol were derived from MD.03
(see Fig. 1B, blot 3). Results from this Gag-Pol combina-
tion indicated that sequences in MD.03 Gag diminished
PR activity.
To localize differences, Gag regions from SpeI through
the D9 site were sequenced and found to be identical
T
Kinetic Parameters Obtained for Cleavage of
PR variant
Substrate 1b
k cat s
21 K m mM k cat/K m mM
21 s21 k cat s
21
HXB2 1.0 (0.1) 60 (8) 0.02 (0.002) 1.7 (0.2)
D1.10 1.7 (0.2) 36 (5) 0.05 (0.008) 2.0 (0.2)
D2.21 2.5 (0.3) 72 (9) 0.03 (0.006) 0.8 (0.1)
MD.03 1.1 (0.1) 25 (3) 0.04 (0.007) 1.8 (0.2)
a Numbers are means (6SD).
b Substrate 1, Lys-Ala-Arg-Val-Leu*Nph-Glu-Ala-Nle-Gly; substrate
Nle*Nph-Glu-Ala-Nle; Nph, p-nitrophenylalanine; Nle, norleucine. Aste
HIVHXB2 is Lys-Ala-Arg-Val-Leu*Ala-Glu-Ala-Met-Ser.through the end of p24 (data not shown). The B- and
D9-cleavage sites were also identical (Fig. 4B). In con-trast, the C sites displayed amino acid polymorphisms in
at least three positions, which were specific for each
patient (Fig. 4B, box). D1.10 (Type I) and D2.21 (Type II)
Gag regions differed by three amino acid residues in the
C-cleavage site. Additional amino acid differences were
localized primarily in one or both zinc-finger domains in
p7NC from MD.03 and involved substitutions between
residues with similar charges (Fig. 4B).
To evaluate further the impact of Gag on PR process-
ing, two additional series of chimeric gag-pol regions
were constructed (Fig. 5). The Gag region from D1.10 was
processed by D2.21 protease somewhat less efficiently
than Gag D2.21 PR, although p24 was produced by either
combination (Fig. 5A, blots 1 and 2). Processing by D1.21
PR was even more diminished when combined with the
Gag region from MD.03 (Fig. 5A, blot 3). Even though
both p54 and p40 accumulated over the course of 1 h,
p25 and p24 were undetectable. Results from D2.21 PR
were similar to D1.10 PR and implicated sequences in
MD.03 Gag that were either resistant to processing or
inhibitory of PR activity.
If processing phenotype of MD.03 PR reflected deter-
minants in Gag, then chimeras between Gag from D1.10
or D2.21 and MD.03 PR should display enhanced pro-
cessing relative to MD.03 Gag. Results of analysis
showed that MD.03 PR could process heterologous Gag
regions D1.10 or D2.21 more efficiently than MD.03 Gag
(Fig. 5B). MD.03 PR cleaved both D1.10 and D2.21 p25 at
the B sites to produce p24 by 60 min (Fig. 5B, blots 2 and
3). Processing by MD.03 PR was changed from Type III to
Type II when combined with different Gag regions.
Analysis of processing by chimeric Gag-Pol regions
indicated that the PR alleles differed in efficiency of
processing the same Gag region. For example, D1.10 Gag
was processed rapidly to p24CA by D1.10 PR (Fig. 4A), but
processed more slowly to p24CA by PR from either D2.21
or MD.03 (Figs. 5A and 5B). Likewise, MD.03 Gag could
be processed to p25 by D1.10 PR within 15 min of induc-
ynthetic Substrates by Variants of HIV-1 PRa
bstrate 2 Substrate 3
M k cat/K m mM
21 s21 k cat s
21 K m mM k cat/K m mM
21 s21
7) 0.04 (0.007) 1.9 (0.9) 67 (9) 0.03 (0.002)
2) 0.10 (0.010) 1.0 (0.1) 39 (5) 0.03 (0.004)
3) 0.04 (0.008) 1.2 (0.2) 18 (3) 0.07 (0.130)
1) 0.12 (0.006) 1.9 (0.2) 43 (7) 0.04 (0.009)
-Ala-Arg-Val-Phe*Nph-Glu-Ala-Nle-Gly; substrate 3, Lys-Ala-Arg-Ile-
signates position of cleavage in the substrate. The B-cleavage site inABLE 1
Three S
Su
K m m
46 (
19 (
19 (
14 (
2, Lystion (Fig. 4A), while processing by PR from either D2.21 or
MD.03 resulted in a significant delay before p25 was
ve p7
142 GOODENOW ET AL.detected (Figs. 5A and 5B). Differences in Gag suscep-
tibility to PR activity by MD.03 could map to the C-
cleavage site and/or to amino acids in p7 (Fig. 5C).
MD.03 had a unique C site, in combination with p7NC
polymorphisms R7K and D48E that differed from p7NC in
either D1.10 or D2.21 Gag.
C site and p7 amino acids contribute to PR
processing of Gag
To identify directly the sequences in MD.03 Gag that
reduced PR processing, combinations of amino acid sub-
stitutions in the C-cleavage site and in p7NC were intro-
duced into MD.03 by site-directed mutagenesis and ver-
ified by sequencing. The C-cleavage site from MD.03
was changed from HLL to SIM (Fig. 6A). In addition, a
substitution from arginine to lysine at amino acid position
7 in MD.03 p7NC was introduced either alone or in com-
bination with a glutamate to aspartate change at position
FIG. 4. Chimeric gag-pol constructs. The gag-pol chimeras were cons
while maintaining D1.10 PR. Each chimeric gag-pol region was fram
immunoblot using p24 monoclonal antibody. Gag-specific proteins are
Lanes A and B, p54Gag and purified p24CA, respectively. Blot 1, D1.10 Gag
amino acid sequences. Patient alleles were aligned to the reference str
acids. Asterisk denotes the location of cleavage in the C site. Bars abo
site through the B-cleavage site (data not shown).48 (Fig. 6A).
Processing by MD.03 PR of the C-site variant with SIMwas unchanged from processing of the natural MD.03 C
site with HLL (Fig. 6B, blots 1 and 2). Processing beyond
p40 was restricted when arginine was substituted for lysine
(Fig. 6, blot 3; C site, K7R) or when aspartate was substi-
tuted for glutamate (E48D, data not shown). In contrast,
E48D substitution in combination with C site and K7R
changes resulted in production of p25 within 15 to 20 min
following induction (Fig. 6, blot 4). Complete processing to
produce p24 was evident by 60 min, concomitant with a
significant decrease in p54 or p40 precursor polyproteins.
Changes in p7NC alone, in the absence of HLL to SIM
substitutions in the C site, failed to accelerate processing
beyond p40 (data not shown). Results are consistent with a
model in which amino acid residues in the C-cleavage site
and in p7NC modulate subsequent processing by PR at the
A- and B-cleavage sites.
DISCUSSION
by exchanging the gag region between SpeI and BglII restriction sites
d following construction. (A) Gag-Pol processing was evaluated by
ed on the left and cleavage sites are indicated on the right of the blot.
1.10 PR; blot 2, D2.21 Gag chimera; blot 3, MD.03 Gag chimera. (B) Gag
LAI. The B, C, and D9 cleavage sites are labeled above the target amino
C designate zinc-finger motifs. All alleles were identical from the SpeItructed
eshifte
indicat
with D
ain HIV
NOur studies show that substitutions of a limited num-
ber of amino acids in PR, which occur in the absence of
seque
143NATURAL POLYMORPHISMS IN HIV-1 GAG IMPACT PROTEASE PROCESSINGdrug selection, can modulate enzyme activity on a variety
of substrates. Amino acid polymorphisms in the flap
region or near the catalytic aspartate influence the ac-
tivity of PR variants that are otherwise identical. In addi-
tion, our studies identified a dominant impact of a small
number of natural amino acid polymorphisms in HIV-1
Gag on PR activity. The amino acids were localized to the
C-cleavage site and to charged amino acid residues in
novel positions in p7NC. A combination of amino acid
differences in the C-cleavage site and in p7NC modulated
subsequent processing by PR at identical A- or B-cleav-
age sites.
The Gag-Pol regions analyzed in our studies repre-
sented the major sequences found in the three patients.
Although the viruses were epidemiologically related, MD
had progressed to AIDS, while the children were rela-
tively asymptomatic. Neither MD nor her children had
received antiretroviral therapy with PI at the time of the
studies. MD died before initiating PI therapy, but both
children subsequently received combination therapy
with ritonavir. D1 experienced only transient viral sup-
pression, while viral burden in D2 was successfully sup-
pressed and maintained at undetectable levels. Although
multiple factors, including clinical variables and PR ge-
FIG. 5. Processing of chimeric Gag regions by D2.21 PR or MD.03 PR.
and p24CA, respectively. Blot 1, D2.21 Gag; blot 2, D1.10 Gag; blot 3, MD.
C, p24CA standard and uninduced control, respectively. Blot 1, MD.03 Ga
p25. (C) Alignment of Gag sequences relative to HIVLAI. Dots above the
D2.21.notype (Perez et al., 2001), influence response to PI
therapy, determinants in Gag that regulate processingand virus replication could be additional factors in the
success of antiretroviral protocols.
Multiple determinants that modulate processing by PR
are distributed throughout Gag, although critical amino
acid residues in p2 or in cleavage sites D9 or D, which
flank p1, have been identified by site-directed mutagen-
esis or drug selection (Doyon et al., 1996; Louis et al.,
1999b; Ott et al., 1999; Pettit et al., 1994; Sheng et al.,
1997; Tessmer and Krausslich, 1998; Yu et al., 1998;
Zybarth and Carter, 1995). These determinants were
identical among the Gag-Pol alleles that we studied.
Amino acid residues in the C-cleavage sites and p7NC
differed among the alleles in our study and were found to
be novel determinants of PR activity. Changes in p2 or
D9- and D-cleavage sites that developed in response to
drug selection in culture failed to affect susceptibility to
PI drugs, but improved Gag processing (Doyon et al.,
1996; Zhang et al., 1997). Likewise, natural variability that
develops in HIV-1 Gag regions in infected patients with-
out drug selection points to selective pressures that
improve PR processing function. Our studies showed
that cleavage site polymorphisms impacted growth by
recombinant viruses. Consequently, determinants in Gag
.21 PR in combination with different Gag regions. Lanes A and B, p54Gag
. (B) MD.03 PR in combination with different Gag regions. Lanes B and
2, D1.10 Gag; blot 3, D2.21 Gag. Asterisks in blots 1, 2, and 3 designate
nce identify positions 7 and 48 in p7NC that differ between MD.03 and(A) D2
03 Gag
g; blotcould contribute to viral fitness and replication in the
absence, as well as in the presence, of PI (Condra et al.,
MD.0
D.03 w
144 GOODENOW ET AL.1995, 1996; Deeks et al., 1998, 1999; Doyon et al., 1998;
Martinez-Picado et al., 1999).
Substitutions by alanine of charged residues in p7NC or
other domains of Gag can have a profound impact on
function (Cimarelli and Luban, 2000; Cimarelli et al.,
2000a,b; Poon et al., 1996). Natural polymorphisms in p7NC
identified in our studies involved exchanges between
amino acids with similar charges, for example basic resi-
dues arginine and lysine or acidic residues glutamate and
aspartate. Thus, an optimal functional relationship requires
more than maintenance of charge interactions. One conse-
quence of mutations in p7NC is reduced packaging of RNA
into virions (Poon et al., 1996). In our study, polymorphisms
in p7NC modulated virus replication in mammalian cells,
which could reflect an impact on RNA packaging. Yet, al-
tered Gag-Pol processing by PR in bacteria was modulated
by changes in p7NC, which indicates an additional func-
tion(s) for p7NC in Gag polyprotein maturation.
Processing at variant C sites continued to produce
p40, but limited subsequent processing at identical A or
FIG. 6. Specific amino acid substitutions in MD.03 Gag changes pro
D2.21 genotype in a series of steps that altered the C site alone, follow
and the C-site change. (B) Processing of mutated MD.03 Gag constru
uninduced control, respectively. Blot 1, Gag processing by wild-type
mutagenesis of the C site and K7R; blot 4, complete processing by MB sites, which was an unexpected result from our stud-
ies. One model to account for the results is that oncecleavage occurs at the C site, dissociation of protein
products from the active site of PR is delayed. Our stud-
ies showed that a combination of amino acid changes in
the C site and in p7NC produced an altered processing
phenotype, which could point to interactions between
p7NC and PR as inhibitory for subsequent cleavage steps.
Results from this study of natural polymorphisms have
implications for understanding the functional relation-
ship between PR and Gag in viruses that emerge in
patients receiving PI therapy. Changes in PR that develop
under selective pressure by inhibitors in patients are
frequently associated with amino acid substitutions in
p7NC or in Gag cleavage sites (Zhang et al., 1997; Doyon
et al., 1998; Mammamo et al., 1998; Rose and Goodenow,
in preparation). While a significant body of research
defines interactions between small peptide inhibitors
and PR (Wlodawer and Erickson, 1993), relatively little
information about interactions between proteins and PR
is available. Experiments to determine the interactions
between p7NC and cleavage sites on PR processing from
g phenotype. (A) Site-directed mutagenesis converted MD.03 gag to a
K7R in combination with the C-site change, and finally E48D plus K7R
MD.03 PR was evaluated. Lanes A, B, and C are p54Gag, p24CA, and
3 Gag-Pol; blot 2, processing of Gag with C-site changes; blot 3,
ith changes in the C site plus K7R and E48D in p7NC.cessin
ed by
cts byviruses that evolve in patients in the absence or pres-
ence of drugs are in progress.
SpeI; K
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Patient gag-pol regions
HIV-1 gag-pol from patient viruses were obtained by
cloning into the pGEM-T Vector System (Promega, Mad-
ison, WI) a 1.7-kb region that was amplified from periph-
eral blood mononuclear cells, as described (Barrie et al.,
1996). Samples representative of the dominant se-
quences at two time points from three patients, a mother
(MD) and her two children (D1 and D2), who were in-
fected by related viruses were used. The mother had
advanced disease (CDC classification C3), while the
children, who were between 2 and 3.5 years of age when
samples were analyzed, were relatively asymptomatic
with little immune suppression (CDC classification A1 or
A2) (Centers for Disease Control, 1998a,b). Previous
analysis showed that the sequences from the three pa-
tients differed by a small number of amino acids in PR, in
Gag p7NC, and in the C-cleavage site between p2 and
p7NC (Barrie et al., 1996). Samples were obtained at a
time when none of the patients had received antiretrovi-
ral therapies that included PI.
The gag-pol expression vector
A plasmid, pGAG-POL, containing a truncated form of
the gag-pol region from HIV-1HXB2 (nucleotides 844 to
3826) (Kuiken et al., 1999), was used as a backbone for
cloning of gag-pol regions from patient viruses. pGAG-
POL was constructed from two plasmids, pDS56-GAG-
C6H and pRT/L10, which were provided by Dr. John Mills
FIG. 7. Construction of pGAG-POL for expression of Gag-Pol. Steps f
Gag polyprotein has the first 18 amino acids of p17MA replaced by 10
Abbreviations for restriction enzyme recognition sites: B, BamHI; Sp,
restriction enzymes that were treated with Klenow.(Le Grice et al., 1988, 1989). pDS56-GAG-C6H contains
an IPTG-inducible promoter and expresses a Gagpolyprotein with the first 18 amino acids of p17 replaced
by 10 amino acids (MRGSHHHGSG) that retain an initial
methionine and include a histidine tag to facilitate puri-
fication for future structural studies. pDS56-GAG-C6H
was digested with XbaI (located in the vector), treated
with the Klenow fragment of Escherichia coli DNA poly-
merase, and digested with BglII (nucleotide 2096) to
generate pGAG (Fig. 7). pRT/L10, which included the pol
region with protease and a portion of RT of HIV-1HXB2, was
digested with KpnI (nucleotide 2836), treated with Kle-
now, and digested with BamHI (within the vector) to
generate the POL fragment (Fig. 7). Following electro-
phoresis and gel purification (Bio-Rad DNA purification
kit; Hercules, CA), the pGAG vector (XbaI-blunt through
BglII) and the BamHI to KpnI-blunt POL fragment were
ligated together. The resulting plasmid construct, pGAG-
POL, was verified by restriction analysis and sequencing.
A region in pGAG-POL extending from SpeI in p24CA to
EcoRV in RT (nucleotides 1507 to 2976) was exchanged
with SpeI to EcoRV gag-pol fragments from patient vi-
ruses. To obtain efficient production of the Gag-Pol
polyprotein, a 11 frameshift was introduced by digestion
of pGAG-POL with BglII, treatment with Klenow, and
religation. The resulting Gag-Pol protein retained the
original amino acid sequence FLGKI from the wild-type
virus without a frameshift, which differs from the amino
acid sequence FFRE produced by the natural 21 frame-
shift. No foreign amino acid residues were introduced by
the BglII-frameshift strategy. Nonframeshifted and frame-
shifted versions of each recombinant construct were
truction of pGAG-POL are outlined under Materials and Methods. The
acids (MRGSHHHGSG) with an initial methionine and a histidine tag.
, KpnI; Bg, BglII; X, XbaI; RV, EcoRV. Asterisks designate products ofor cons
aminogenerated and verified by sequencing.
Chimeric Gag-Pol regions were constructed by diges-
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and BglII to excise and replace the gag region with a
SpeI/BglII gag fragment from a different virus. Once each
chimeric pGAG-POL plasmid was constructed, a 11
frameshift was introduced as described. Site-directed
mutagenesis of residues within the gag region was per-
formed using the Quik Change kit (Stratagene, La Jolla,
CA) and verified by sequencing.
Expression and analysis of the Gag-Pol polyprotein
The pGAG-POL plasmid was transformed into compe-
tent E. coli M15 pDMI.1 cells supplied by Dr. John Mills
(Certa et al., 1986). Overnight cultures were expanded in
50 ml of LB medium supplemented by 100 mg of ampi-
cillin per ml and 25 mg of kanamyacin per ml and grown
until an OD600 of 0.8 was reached. To induce expression,
400 mg IPTG per ml was added. Aliquots of cells were
removed at 0, 5, 10, 15, 20, 30, and 60 min following
induction. Cells were pelleted and lysed by resuspen-
sion in Laemmli sample buffer (LSB) [100 mM Tris–Cl (pH
6.8), 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol
blue, and 20% glycerol]. Lysates from equivalent
amounts of cells were analyzed by 10% Tris–tricine SDS–
polyacrylamide gel electrophoresis (PAGE) for approxi-
mately 1 h at constant voltage. Gels were blotted onto
Immobilon-P membranes (Millipore Corp., Bedford, CT)
in 10 mM MES (pH 8.3) buffer for 10–12 h at 25 mA at
10°C. Processing of Gag-Pol polyprotein over time was
visualized by immunoblotting. Membranes were blocked
for 1 h in the presence of 5% nonfat dried milk in 0.1%
Tween 20 in Tris-buffered saline (TTBS) containing 25
mM Tris (pH 7.4). A primary mouse monoclonal antibody
to p24CA was obtained from the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH (Steimer et al., 1986). Incubation of membranes with
a 1:10,000 dilution of the primary p24 antibody was per-
formed in TTBS buffer containing 5% nonfat dried milk.
Binding of the primary antibody was detected using a
secondary goat anti-mouse antibody conjugated to
horseradish peroxidase (Bio-Rad) and visualized by en-
hanced chemiluminescence (Amersham Life Science,
Buckinghamshire, England) using the standard protocol
supplied by the manufacturer.
Expression and kinetic analysis of protease
The 297 bp encoding HIV-1 PR from HIVHXB2 or from
patient gag-pol regions was subcloned into an E. coli
expression vector to obtain purified protein for kinetic
characterization. Cloning, expression, and purification
procedures for the PR protein have been described (Ido
et al., 1991).
Purified PR from four different PR variants was used
for kinetic analyses to obtain values for K m, k cat, and
k cat/K m. K m values were obtained using a diode array
spectophotometer (Model 8452; Hewlett–Packard).Briefly, a range of concentrations of synthetic substrates,
which mimicked the Leu*Ala junction at the B-cleavage
site between p24CA and p2 in Gag and included a p-
nitrophenylalanine reporter group at the P19 position,
were used to monitor a shift in maximum absorbance
from 280 to 272 nm. Substrate concentrations ranged
from 10 to 120 mM, while enzyme concentration re-
mained constant. Enzyme and buffer [0.1 M Na acetate
(pH 4.7), 0.3 M NaCl] were incubated 3 min at 37°C prior
to addition of substrate, followed by monitoring of the
absorbance changes in the range of 284–324 nm. Initial
rates of cleavage of the substrate were plotted versus
substrate concentration. Analysis of the resulting curves
by Marquardt methods yielded values of V max and K m. The
total enzyme concentration (E T) was determined by ac-
tive site titration using a tight-binding inhibitor. The k cat is
the value obtained from the quotient V max/E T. All values
determined have a standard deviation less than 20%.
Generation of recombinant viruses
HIV-1 molecular clone pLAI.2 (provided by Keith Pe-
den) was used for construction of recombinant viruses
(Peden et al., 1991). The SpeI site in position 7 of pLAI.2
upstream of the 59 LTR was removed by oligo-linker
insertional mutagenesis to produce pLAI.4. Patient gag-
pol regions were excised from pGAG-POL by digestion
with SpeI and a unique BstZ17I, located 52 bp upstream
of the EcoRV site in RT. BstZ17I was used in place of
EcoRV to construct recombinant viruses because addi-
tional EcoRV sites appear in other regions of the viral
genome.
Recombinant virus constructs were transfected into
HEK293 cells that were grown in Dulbecco’s modified
Eagle’s medium with 10% fetal calf serum (FCS) (Rice and
Mathews, 1988). Supernatants were collected after 48 h,
filtered, stored at 280°C, and analyzed for p24 antigen
by ELISA (Coulter, Miami, FL). Virus stocks were titered
in PBMC that were stimulated with phytohemaglutinin
(PHA) and cultured in RPMI 1640 containing 15% FCS
and interleukin-2 (30 U/ml). TCID50 values were calcu-
lated by the Spearman–Karber method (Division of AIDS,
1997).
Virus replication assays
Kinetics of replication were evaluated in Jurkat T cells
and in PBMC. Jurkat E6-1 cells (1.2 3 106) were infected
by 2000 TCID50 per ml of a virus stock (Weiss et al., 1984).
Cultures were maintained in RPMI 1640 with 10% FCS.
PHA-stimulated PBMC (2 3 105) obtained by Ficoll–
Hypaque density centrifugation from leukophoresis were
infected by 1000 TCID50 per ml of virus stock. PBMC
cultures were maintained in RPMI 1640 with 15% FCS
and interleukin-2 (30 U/ml). Supernatant p24 antigen lev-
els were determined by ELISA (Coulter).
147NATURAL POLYMORPHISMS IN HIV-1 GAG IMPACT PROTEASE PROCESSINGGag-Pol processing in Jurkat cells
Jurkat E6-1 cells (30 3 106) were transfected with 20
mg of recombinant gag-pol virus plasmid DNA using
SuperFect (Qiagen, Valencia, CA). The cells were
washed 2 h postinfection by addition of PBS (phosphate-
buffered saline) followed by centrifugation. Cells were
resuspended in 5 ml fresh medium (10% FCS, 1% peni-
cillin–streptomycin in RPMI 1640 containing L-glutamine)
at a final concentration of 2.5 3 105 cells/ml and incu-
bated in T-25 flasks. One flask was collected at 0, 48, 60,
72, 80, and 96 h for lysate preparation. Prior to lysis cells
were pelleted and washed twice with PBS. Cells were
lysed with M-Per Mammalian Protein Extraction Reagent
(Pierce, Rockford, IL) in the presence of a protease in-
hibitor cocktail (Sigma, St. Louis, MO) for 10 min at room
temperature. Samples were centrifuged at 27,000 g at
10°C for 15 min to remove cellular debris. The superna-
tant was stored at 280°C until further use.
Total protein was determined for each sample using
the BCA-200 protein assay kit (Pierce). Samples were
boiled in LSB for 10 min and 25 mg protein was loaded
per sample on a 12% SDS–PAGE gel. Immunoblots for
evaluating Gag-Pol polyprotein processing were identi-
cal to the methods used for analysis of bacterial protein
expression.
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